SecBot SecBot
8-K ·Filed Jul 27, 2026

OPK

OPKO HEALTH, INC.
MIXED
Impact 5/10
Horizonweeks Processed3mo ago SEC0001193125-26-318069
8-K Item 2.02: Earnings release
Actionable Insight ◆ Mixed

The headline beat is misleading due to non-recurring items. Monitor the Q3 2026 earnings for organic revenue growth in diagnostics and pharmaceuticals, and track cash burn rate. The raised full-year guidance provides a positive narrative, but the underlying business trends remain weak.

DirectionMixed
Confidencemedium
Horizonweeks

Drug in focus

OPK drug pipeline →

OPK-8801001

● Neutral Named in this 8-K
Impact
Phase
Phase 1/2a
Time to market
At least 5-7 years, assuming successful completion of Phase 1/2a, Phase 2, and Phase 3 trials followed by regulatory filing and review.
Next catalyst
None dated

What to watchOPK-8801001 just began Phase 1/2a dosing on October 27, 2026, so the next meaningful catalyst is initial safety and pharmacodynamic data, likely not for 12+ months. For OPKO Health, the bigger near-term drivers are the Labcorp/BioReference asset sale closing and NGENLA royalty revenue trends. This early-stage program is unlikely to move the stock in the foreseeable future.

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$1.65
T+0 close · Jul 27, 2026 · via day close
Latest settled
−3.03%
T+60 · $1.60
Vs SPY
−7.38%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jul 28 $1.65entry
  2. T+1 · 4mo ago −17.27%α −15.73% · $1.37
  3. T+5 · 4mo ago −20.61%α −22.88% · $1.31
  4. T+20 · 3mo ago −9.70%α −13.08% · $1.49
  5. T+60 · 27d ago −3.03%α −7.38% · $1.60
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

OPKO Health reported Q2 2026 revenue of $163.5M, above the $131.2M consensus estimate, and a net loss of $0.01 per share, significantly beating the consensus estimate of -$0.11. The beat was driven by a $29.4M non-cash revenue recognition from shares received in the Nicoya agreement amendment and a $18.1M earnout from the Labcorp asset sale, masking ongoing weakness in core diagnostics revenue, which fell to $74.5M from $101.1M a year ago. Full-year revenue guidance was raised to $560M-$585M from the prior $530M-$560M range, but the company remains unprofitable with an operating loss of $7.0M, and the quality of the beat is low due to its reliance on non-recurring items.

Key Financial Metrics

EPS
−$0.01
est −$0.11 · +90.9%
Revenue
$163.5M
est $131.2M · +24.6% · +4.3% YoY
Rating
beat
Guidance
$560M-$585M
raised

Key Facts

  • Q2 2026 total revenue of $163.5M vs $156.8M YoY, beating consensus of $131.2M.
  • Net loss of $0.01 per share vs consensus -$0.11, a 90.9% beat.
  • Revenue beat driven by $29.4M non-cash revenue from Nicoya equity stake and $18.1M Labcorp earnout.
  • Core diagnostics revenue declined to $74.5M from $101.1M YoY, impacted by the Labcorp asset sale.
  • Full-year 2026 revenue guidance raised to $560M-$585M from prior $530M-$560M.
  • Cash burn continues: cash & equivalents fell to $300.8M from $369.1M at year-end 2025.
  • Operating loss improved to $7.0M from $60.0M YoY, but still negative.

Financial Impact

Revenue beat of $32.3M vs consensus, but $29.4M of that is non-cash from a licensing amendment. Core operations remain loss-making.

revenueepscashoperating income

Risk Factors

  • Core diagnostics revenue continues to decline post-Labcorp sale.
  • Cash burn of ~$68M in H1 2026 reduces financial flexibility.
  • Dependence on non-recurring items (Nicoya, Labcorp earnout) for revenue growth is unsustainable.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
70% bullish (10 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-318069
Document: opk-20260727.htm0001193125-26-318069
Document: 0001193125-26-318069-index-headers.html0001193125-26-318069
Document: 0001193125-26-318069-index.html0001193125-26-318069
Document: 0001193125-26-318069.txt0001193125-26-318069
8-K Data (Synthetic)0001193125-26-318069

US Market Status

Market Closed · Opens in 6h 7m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jul 27, 2026